FDA Clears IND for Pasithea's PAS-004 in Cutaneous Neurofibromas, Opening Second Phase 2 Path
KTTA sits 28% above its 52-week low of $0.281.
Summary
The FDA cleared Pasithea's IND for PAS-004 in NF1-associated cutaneous neurofibromas, letting the company run a randomized, placebo-controlled Phase 2 trial in the US. This is the second indication the company is pursuing for its oral macrocyclic MEK inhibitor, alongside the ongoing Phase 1/1b work in plexiform neurofibromas. Management frames the opportunity as a multibillion-dollar market with no FDA-approved systemic therapy for cNF, a condition present in over 95% of NF1 patients; the company estimates more than 80,000 US NF1 patients have moderate-to-severe cNF burden. For a micro-cap clinical-stage biotech, a cleared IND is a real de-risking step but not a data readout — the value hinges on trial start and eventual Phase 2 results. Note the timeline: Nasdaq granted a 180-day extension to February 16, 2027 to regain the $1.00 minimum bid, and stockholders approved a reverse split in September, so the stock remains under listing pressure. The company reported a $50.4 million cash balance in its last 10-Q, which funds the expanded R&D plan for now.
At the time of this announcement, KTTA was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.3M. The 52-week trading range was $0.28 to $2.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.